Key result
Macitentan and selexipag regimens are linked to a ~0.15 increase in low-risk criteria in PAH.
Why the study?
Does treatment with macitentan and/or selexipag improve non-invasive risk parameters and quality of life in patients with pulmonary arterial hypertension at low or intermediate mortality risk?
Observational (n=176)
Yes
Does treatment with macitentan and/or selexipag improve non-invasive risk parameters and quality of life in patients with pulmonary arterial hypertension at low or intermediate mortality risk?
In a real-world Italian cohort of PAH patients, treatment with macitentan and/or selexipag was associated with improved non-invasive risk criteria and REVEAL scores at 12 months, suggesting disease stabilization.
Answers are grounded in this paper and cite their sources.
Supports macitentan/selexipag combination to improve PAH risk profiles; extends prior evidence to real-world settings.
BACKGROUND: Pulmonary arterial hypertension (PAH) is a progressive disease associated with significant morbidity and mortality. Combination therapy targeting multiple pathways has been shown to improve clinical outcomes. METHODS: The INSPECTIO study was a prospective, multicenter, observational study conducted across 29 Italian centers specializing in PAH management. The study sought to explore the impact of combination therapy on disease progression and quality of life, by assessing non-invasive risk parameters, echocardiographic and hemodynamic conditions, and patient-reported outcomes (PROs). Patients with PAH at low or intermediate mortality risk, treated with macitentan and/or selexipag (as monotherapy or in combination), were enrolled. Data on non-invasive low-risk criteria (WHO Functional Class, 6-min walk distance [6MWD], and NT-proBNP), REVEAL risk scores, echocardiographic and hemodynamic parameters, and patient-reported outcomes (emPHasis-10) were collected at baseline and 12 months. A Narrative Medicine analysis complemented quantitative findings by exploring patients' experiences. RESULTS: Among 176 patients with follow-up data, the number of non-invasive low-risk criteria increased by an average of 0.15 at 12 months (p = 0.0167). REVEAL 2.0 and REVEAL Lite 2 scores showed significant reductions (mean changes: -1.0, p = 0.0142; -0.8, p = 0.0111, respectively). Modest changes were observed in echocardiographic and hemodynamic parameters. Narrative analysis highlighted strengthened patient-provider relationships and improved coping strategies. Safety outcomes aligned with known profiles. CONCLUSIONS: The INSPECTIO study supports the effectiveness of guideline-directed therapy and regular risk assessment to optimize treatment strategies in PAH. The increase in non-invasive low-risk criteria suggests a stabilization of disease over 12 months.
No takes yet. Share an insight, caveat, or question.
D'Alto et al. (2026) conducted an observational in Pulmonary arterial hypertension (n=176). Macitentan and/or selexipag was evaluated on Number of non-invasive low-risk criteria (mean change 0.15, p=0.0167). Treatment with macitentan and/or selexipag in PAH patients increased the number of non-invasive low-risk criteria by an average of 0.15 at 12 months.
Synapse has enriched 10 related papers. Consider them for comparative context: